Methicillin-resistant Staphylococcus aureus (MRSA) is a bacterial scourge. As its name suggests, MRSA is resistant to most common antibiotics and thus difficult to treat, particularly in children where it commonly causes complicated skin and skin structure infections.
In a randomized, controlled clinical trial -- the first of its kind -- a multi-institution research team reports that daptomycin, part of a new class of antibiotics currently approved only for use in adults, is effective and well-tolerated in children. The findings are published in the March 2017 issue of Pediatrics.
"The safety and efficacy of intravenous daptomycin was comparable to standard-of-care IV antibiotics used for hospitalized children, usually vancomycin or clindamycin for MRSA and cefazolin for methicillin-susceptible strains of S. aureus," said first author John Bradley, MD, professor of clinical pediatrics, co-chief of the Division of Infectious Diseases at UC San Diego School of Medicine and director of the Division of Infectious Diseases at Rady Children's Hospital-San Diego.
"Daptomycin should provide a safe and effective alternative to vancomycin, clindamycin or linezolid for IV treatment of invasive MRSA skin infections. Concerns for vancomycin renal toxicity and clindamycin antibiotic resistance were not present. There was no evidence of daptomycin toxicity in the trial."
The Food and Drug Administration is currently reviewing whether to approve daptomycin use in children.
MRSA infections are commonly associated with patients in hospitals and nursing homes whose immune systems are weakened, but community-associated MRSA (CA-MRSA) is widespread, readily transmitted at daycare centers, playgrounds and in schools where children have frequent skin-to-skin contact, share toys that have not been cleaned and are more likely to have scrapes, abrasions and bites that offer potential infection entry points.
CA-MRSA usually causes skin infections but can lead to more serious consequences, such as pneumonia and infections of bones and joints. Daptomycin is active against MRSA and was approved for use in adults in 2003 for treatment of skin and skin structure infections, and for bloodstream infections three years later.
The new study was a prospective, randomized, investigator-blinded study that included more than 250 daptomycin-exposed children, ages 1 to 17, to document safety and efficacy of the antibiotic in treating pediatric skin and skin structure infections. Dosing was based on adult experience, but researchers found that the younger the child, the more quickly their bodies eliminated daptomycin. Thus pediatric doses increased as the age of the research participants decreased.
"Most news these days is about the declining utility of antibiotics as microbial resistance becomes more widespread and intractable," said Bradley. "These findings are encouraging. Daptomycin appears to be a suitable, once-a-day alternative to existing antibiotics with harsher side effects."
Co-authors include: Chad Glasser, Hernando Patino, Minjung Yoon, Diane Anastasiou, Dominik Wolf, and Paula Bokesch, Merck; Sandra L.R. Arnold, University of Tennessee; Antonio Arrieta, Children's Hospital of Orange County; Blaise Congeni, Akron Children's Hospital, Ohio; Robert Daum, University of Chicago MRSA Research Center; and Tsoline Kojaoghlanian, Children's Hospital at Montefiore, Bronx, NY.
Disclosure: Bradley, Arnold, Arrieta, Congeni, Daum and Kojaoghlanian were study site principal investigators whose respective employers received institutional research funding from the study sponsor, Merck. Additionally, UC San Diego received funding from Cubist Pharmaceuticals, now part of Merck, to advise Cubist on clinical trial design.
Scott LaFee | EurekAlert!
Scientists find new approach that shows promise for treating cystic fibrosis
14.03.2019 | NIH/National Heart, Lung and Blood Institute
Lab grown ‘brains’ successfully model disease
13.03.2019 | Max-Planck-Institut für Psychiatrie
New research group at the University of Jena combines theory and experiment to demonstrate for the first time certain physical processes in a quantum vacuum
For most people, a vacuum is an empty space. Quantum physics, on the other hand, assumes that even in this lowest-energy state, particles and antiparticles...
Physicists in the EPic Lab at University of Sussex make crucial development in global race to develop a portable atomic clock
Scientists in the Emergent Photonics Lab (EPic Lab) at the University of Sussex have made a breakthrough to a crucial element of an atomic clock - devices...
Every year earthquakes worldwide claim hundreds or even thousands of lives. Forewarning allows people to head for safety and a matter of seconds could spell...
Scientists of the Department of Physics at the University of Hamburg, Germany, detected the magnetic states of atoms on a surface using only heat. The...
Combining an atomically thin graphene and a boron nitride layer at a slightly rotated angle changes their electrical properties. Physicists at the University of Basel have now shown for the first time the combination with a third layer can result in new material properties also in a three-layer sandwich of carbon and boron nitride. This significantly increases the number of potential synthetic materials, report the researchers in the scientific journal Nano Letters.
Last year, researchers in the US caused a big stir when they showed that rotating two stacked graphene layers by a “magical” angle of 1.1 degrees turns...
11.03.2019 | Event News
01.03.2019 | Event News
28.02.2019 | Event News
15.03.2019 | Medical Engineering
15.03.2019 | Life Sciences
15.03.2019 | Life Sciences